NCT04908111 2026-04-06
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1
Cancer Research UK
Phase 1/2 Suspended
Clinical Trials
24 trialsNCT07366658 2026-01-26
NEUK203-13
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1 Not yet recruiting
NCT05608148 2025-11-18
Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors
Kyushu University
Phase 1 Recruiting
NCT06348719 2025-09-15
ROBOT-ECO-GYN
Rennes University Hospital
Phase NA Recruiting
NCT05884983 2025-08-15
Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma
Zhongshan People's Hospital, Guangdong, China
Recruiting
NCT05843539 2025-07-22
CAPONE
University of Lorraine
Completed
NCT01430390 2025-06-11
In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT06144762 2025-02-12
PANC-O-MICS
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Recruiting
NCT02828202 2025-02-11
MelBase
Assistance Publique - Hôpitaux de Paris
Recruiting
NCT06777264 2025-01-15
JUVENTAS-ALL05
First Affiliated Hospital of Zhejiang University
Phase 2 Not yet recruiting
NCT03549000 2024-12-13
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Novartis
Phase 1 Terminated
NCT04283539 2023-11-13
Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy
National Jewish Health
Unknown
NCT00014131 2023-10-04
Vaccine Therapy in Treating Patients With Kidney Cancer
Lisata Therapeutics, Inc.
Phase 1 Terminated
NCT04382352 2023-03-24
B002-101
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1 Completed
NCT02529930 2022-07-13
An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)
Nykode Therapeutics ASA
Phase 1/2 Completed
NCT04436133 2022-05-06
Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
National Vaccine and Serum Institute, China
Phase 2 Completed
NCT02128230 2021-06-22
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
Phase 2 Terminated
NCT01413087 2019-11-01
LAPC-BC-819
Anchiano Therapeutics Israel Ltd.
Phase 2 Terminated
NCT03383952 2017-12-27
A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia
Immune Cell, Inc.
Phase 1 Unknown
NCT03383965 2017-12-27
CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas
Immune Cell, Inc.
Phase 1 Unknown
NCT01974869 2017-02-07
Anti Tumor Necrosis Factor Alpha Agents and Surgical Stress Response
El-Hussuna, Alaa, M.D.
Completed
NCT02806934 2016-06-21
TNF Polymorphism and Implantation Rate
Centre Hospitalier Universitaire de Nice
Completed
NCT01349647 2016-01-05
Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01250314 2012-07-03
OSTEHOM
Assistance Publique - Hôpitaux de Paris
Phase NA Completed